A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated® human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease-Reference-Cited by-同舟云学术

A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated® human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease

Published:2007-07 Issue:1 Volume:39 Page:115-118
ISSN:1079-9796
Container-title:Blood Cells, Molecules, and Diseases
language:en
Short-container-title:Blood Cells, Molecules, and Diseases

Author:

Zimran Ari,Loveday Kenneth,Fratazzi Candida,Elstein Deborah

Publisher

Elsevier BV

Subject

Cell Biology,Hematology,Molecular Biology,Molecular Medicine

Reference10 articles.

1. Gaucher disease;Beutler,2001

2. Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's disease;Barton;N. Engl. J. Med.,1991

3. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry;Weinreb;Am. J. Med.,2002

4. Therapeutic goals in the treatment of Gaucher disease;Pastores;Semin. Hematol.,2004

5. Individualization of long-term enzyme replacement therapy for Gaucher disease;Andersson;Genet. Med.,2005

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies;Biotechnology Advances;2023-10

2. Quantitative assessment of the exposure–efficacy relationship of glucocerebrosidase using Markovian elements in Gaucher patients treated with enzyme replacement therapy;British Journal of Clinical Pharmacology;2022-01-10

3. Current and Emerging Pharmacotherapy for Gaucher Disease;Clinical Reviews in Bone and Mineral Metabolism;2019-11-20

4. Relationship Between Glucocerebrosidase Activity and Clinical Response to Enzyme Replacement Therapy in Patients With Gaucher Disease Type I;Basic & Clinical Pharmacology & Toxicology;2018-03-30

5. Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4 years in phase 3 trials;Blood Cells, Molecules, and Diseases;2018-02